Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.

Author: BondiskeyPhung, ChaJang-Ho, FaulknorJanice, KennedyWilliam P, Levy-CoopermanNaama, LewisNicole M, LiXiaodong, LiuWen, McCreaJacqueline B, PanebiancoDeborah L, SchoedelKerri A, SellersEdward M, SunHong, TroyerMatthew D, WagnerJohn A

Paper Details 
Original Abstract of the Article :
Suvorexant is a dual orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia at a maximum dose of 20 mg. This randomized double-blind crossover study evaluated the abuse potential of suvorexant in 36 healthy recreational polydrug users with a history of sedat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1097/JCP.0000000000000516

データ提供:米国国立医学図書館(NLM)

Suvorexant: A Dual Orexin Receptor Antagonist for Insomnia

Insomnia, the persistent inability to fall asleep or stay asleep, can significantly disrupt an individual's quality of life. This study examines the abuse potential of suvorexant, a dual orexin receptor antagonist approved for the treatment of insomnia. Picture this research like a group of scientists carefully evaluating a new type of desert plant, seeking to understand its potential benefits and risks.

The researchers conducted a randomized, double-blind, crossover study to compare the abuse potential of suvorexant with zolpidem, a commonly used sedative-hypnotic medication. They found that suvorexant demonstrated abuse potential, similar to zolpidem, but with a lower incidence of abuse-related adverse events. Think of this like a group of explorers discovering a new and potentially valuable desert resource, but also recognizing its potential risks and limitations.

Balancing Efficacy and Safety

This research highlights the importance of balancing efficacy and safety in the development and use of medications for insomnia. While suvorexant shows promise as a treatment for insomnia, it’s important to be aware of its potential for abuse. Think of this like a group of desert travelers carefully weighing the benefits of a shortcut against the potential risks associated with navigating unknown territory.

The Importance of Responsible Use

This study underscores the importance of responsible use of medications for insomnia. Healthcare professionals must carefully assess patient needs and risks, prescribing these medications appropriately and monitoring their use closely. Think of this like a skilled desert guide who carefully chooses routes and monitors the health of their caravan, ensuring their safety and well-being throughout the journey.

Dr.Camel's Conclusion

This study sheds light on the potential benefits and risks associated with suvorexant, a new medication for insomnia. It emphasizes the importance of balancing efficacy with safety and the need for responsible use of medications for sleep disorders. Remember, dear reader, just as a camel caravan must carefully choose its path through the desert, healthcare professionals must carefully consider all factors when making treatment decisions for their patients.

Date :
  1. Date Completed 2017-04-12
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

27253658

DOI: Digital Object Identifier

10.1097/JCP.0000000000000516

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.